Regeneron (NASDAQ: REGN) reported Q4 EPS of $5.23, $0.70 better than the analyst estimate of $4.53. Revenue for the quarter came in at $1.58 billion versus the consensus estimate of $1.5 billion.

• Fourth quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 14% to $975 million versus fourth quarter 2016 and full year 2017 EYLEA U.S. net sales increased 11% to $3.70 billion versus full year 2016
• Fourth quarter 2017 EYLEA global net sales(1) increased 19% to $1.61 billion versus fourth quarter 2016 and full year 2017 EYLEA global net sales(1) increased 14% to $5.93 billion versus full year 2016

For earnings history and earnings-related data on Regeneron (REGN) click here.